ZNF217 and acute myeloid leukemia: Analysis using the SangerBox database indicated that ZNF217 expression is significantly elevated in AML (Figure 1B), then we categorized 142 patients with AML into “high ZNF217 expression” and “low ZNF217 expression” groups based on the median expression value and subsequently compared their survival differences, the results imply that the low ZNF217 expression group might have a better prognosis.